Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
dinaciclib (MK-7965)
i
Other names:
MK-7965, SCH 727965, MK 7965, SCHOOL 727965, PS-095760, SCH-727965, NSC 747135
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(4)
News
Trials
Company:
Ligand, Merck (MSD)
Drug class:
CDK inhibitor
Related drugs:
‹
SNS-032 (4)
PHA 793887 (1)
AT7519 (0)
R-547 (0)
RGB-286638 (0)
E7070 (0)
P27600 (0)
BAY1000394 (0)
SNS-032 (4)
PHA 793887 (1)
AT7519 (0)
R-547 (0)
RGB-286638 (0)
E7070 (0)
P27600 (0)
BAY1000394 (0)
›
Associations
(4)
News
Trials
VERI cancer hierarchy
Reset Filters
MYC expression
Triple Negative Breast Cancer
MYC expression
Triple Negative Breast Cancer
pembrolizumab + MK-7965
Sensitive: C3 – Early Trials
pembrolizumab + MK-7965
Sensitive
:
C3
pembrolizumab + MK-7965
Sensitive: C3 – Early Trials
pembrolizumab + MK-7965
Sensitive
:
C3
CCNE1 amplification
Ovarian Cancer
CCNE1 amplification
Ovarian Cancer
MK-7965
Sensitive: D – Preclinical
MK-7965
Sensitive
:
D
MK-7965
Sensitive: D – Preclinical
MK-7965
Sensitive
:
D
FLT3-ITD expression
Acute Myelogenous Leukemia
FLT3-ITD expression
Acute Myelogenous Leukemia
gilteritinib + MK-7965
Sensitive: D – Preclinical
gilteritinib + MK-7965
Sensitive
:
D
gilteritinib + MK-7965
Sensitive: D – Preclinical
gilteritinib + MK-7965
Sensitive
:
D
RAC1 P29S
Melanoma
RAC1 P29S
Melanoma
MK-7965
Sensitive: D – Preclinical
MK-7965
Sensitive
:
D
MK-7965
Sensitive: D – Preclinical
MK-7965
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login